Our Innovation Pipeline
A focused portfolio of biologic and vaccine candidates targeting key regional health challenges.
Pre-clinical
SVX-201
Monoclonal Antibody for MERS-CoV
SVX-V101
Next-Gen Meningitis Vaccine
Phase I
SVX-305
Biosimilar for Autoimmune Diseases
Phase II
SVX-101
Novel Biologic for Metabolic Disorders
Core Technology Platforms
Our end-to-end capabilities enable rapid development and scalable manufacturing.
Cell Line Engineering
Proprietary CHO cell platforms optimized for high-yield, stable expression of complex proteins and monoclonal antibodies.
Process Development
End-to-end process development from upstream perfusion to downstream purification, designed for scalability and regulatory compliance.
Analytical Sciences
Comprehensive suite of analytical methods for product characterization, stability testing, and release, ensuring quality and safety.
Our Scientific Leadership
Meet the minds driving our scientific vision and execution.
Dr. Arwa Al-Sayed
Chief Scientific Officer
PhD in Molecular Biology from Stanford University, with over 20 years of experience leading R&D teams at major global biopharma companies.
Dr. Fahad Al-Mutairi
Head of Process Development
Expert in bioprocess engineering from MIT, responsible for scaling some of the industry's most successful biologics from lab to commercial scale.
Dr. Noura Al-Ghamdi
Director of Vaccine Research
Leading immunologist from KAUST with pioneering research in adjuvant technology and rapid-response vaccine platforms.